Myriad to Announce Fiscal Third-Quarter 2018 Financial Results on May 8, 2018

SALT LAKE CITY, April 17, 2018 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal third-quarter 2018 sales and earnings conference call with investors and analysts at 7:30 a.m. ET on Tuesday, May 8, 2018.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, will provide an overview of Myriad’s financial performance for the fiscal third-quarter and provide a business update. Additionally, Dr. Bryan Dechairo, executive vice president of Clinical Research, will discuss the data from the GeneSight randomized controlled trial. The clinical study data will first be presented as a late breaking poster in the exhibit hall at the American Psychiatric Association annual meeting on Monday, May 7, 2018 at 10:00 a.m. ET, and will be presented by the study principal investigator the same day at a satellite symposium at 6:30 p.m. ET at Hudson Mercantile at 500 W. 36^th Street in New York City. 

To listen to the earnings call, interested parties in the United States may dial 800-699-0623 or +1 303-223-4362 for international callers.  All callers will be asked to reference reservation number 21887258. The conference call also will be available through a live webcast and a slide presentation pertaining to the earnings call will also be available under the investor section of our website at www.myriad.com.  A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers and entering reservation number 21887258.

About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on five strategic imperatives:  building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.